Beam Therapeutics (BEAM) Profit After Tax (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Profit After Tax data on file, last reported at -$96.5 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 10.92% year-over-year to -$96.5 million in Q1 2026; TTM through Mar 2026 was $147.8 million, a 138.15% increase from a year earlier, with the FY2025 full-year figure at -$79.6 million, up 78.88% from the prior year.
• Profit After Tax for Q1 2026 stood at -$96.5 million, down from $244.7 million in the prior quarter.
• Over the last five years, Profit After Tax for BEAM reached as high as $244.7 million in Q4 2025 and fell as low as -$110.1 million in Q3 2022.
• Historically, Profit After Tax has averaged -$44.4 million across 5 years, with a median of -$91.1 million in 2024.
• Across the five-year window, Profit After Tax plunged 291.42% in 2022 and jumped 503.91% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$36.1 million in 2022, then soared by 503.91% to $145.8 million in 2023, then slumped by 162.7% to -$91.4 million in 2024, then surged by 367.66% to $244.7 million in 2025, then tumbled by 139.43% to -$96.5 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$96.5 million in Q1 2026, $244.7 million in Q4 2025, and -$200000.0 in Q3 2025.